ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoantigens"

  • Abstract Number: 1591 • ACR Convergence 2025

    Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis

    Zsuzsanna McMahan1, Claudia Pedroza2, Katie Lee3, Bingrui Chen3, Ami Shah4, Jody Hooper5, Srinivas Puttapaka6, Livia Casciola-Rosen7 and Subhash Kulkarni8, 1UT Health Houston, Houston, TX, 2UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, 3UTHealth Houston, Houston, TX, 4Johns Hopkins Rheumatology, Baltimore, MD, 5Stanford University, Stanford, CA, 6BIDMC/Harvard, Boston, MA, 7Johns Hopkins University, Baltimore, MD, 8BIDMC, Boston, MA

    Background/Purpose: Gastrointestinal (GI) dysfunction is common and often debilitating in systemic sclerosis (SSc). Though it affects most patients, mechanisms are poorly understood and biomarkers for…
  • Abstract Number: 1524 • ACR Convergence 2025

    Hydroxychloroquine Reduces Autoantibody Levels in Persons at Risk for Systemic Lupus Erythematosus

    David Karp1, Prithvi Raj1, Changsong Zhu1, Dajiang Liu2, Duanping Liao2 and Nancy Olsen3, 1UT Southwestern Medical Center, Dallas, TX, 2Penn State College of Medicine, Hershey, PA, 3Penn State University/Milton S Hershey, Hershey, PA

    Background/Purpose: The Study of Antimalarials in Incomplete Lupus Erythematosus (SMILE, NCT03030118) was a double-blind, randomized, placebo-controlled study of hydroxychloroquine (HCQ) to prevent the development of…
  • Abstract Number: 1514 • ACR Convergence 2025

    Serum Antigenome Profiling Reveals Diagnostic Models for Systemic Lupus Erythematosus

    Yan Wang1, Lulu Cao2, Mengze Xu3, Jian Lu3, Jing He1, Fanlei Hu4 and Zhanguo Li5, 1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, China (People's Republic), 2Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, 3State Key Laboratory of Protein and Plant Gene Research, Center for Bioinformatics, School of Life Sciences, Peking University, Beijing, China., Beijing, Beijing, China (People's Republic), 4Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic), 5Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, Beijing, China (People's Republic)

    Background/Purpose: Systemic lupus erythematosus (SLE) exhibits profound clinical and pathogenic heterogeneity, complicating diagnosis and treatment. Identifying subtype-specific biomarkers might intrinsically link to organ involvement.Methods: Patients…
  • Abstract Number: 0997 • ACR Convergence 2025

    Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan 

    Olivia Pryor1, Catalina Burbano2, Nathaniel Bagge2, Rutuja Kulkarni2, Heather F. Jones2, Livio Dukaj2, Shoshana M.K. Bloom2, Jackson Lirette2, Rachel Lent2, Prachi Dhanania2, Nicole A. Ladd2, Ryan Kritzer2, Hana Husic2, Shobitha Jillella2, Candace R. Perullo2, Jinyu Zhu2, Teagan J. Parsons2, Ira Jain2, Rakshika Balasubramaniyam2, Kenneth L. Jahan2, Vivin Karthik2, Alexander Cristofaro1, Chandan K. Pavuluri2, Jenna LaBelle2, Laurie Barefoot2, Shrikanta Chattopadhyay2, Kim M. Cirelli2, Mollie M. Jurewicz2, Andrew P. Ferretti2 and Cagan Gurer2, 1TScan Therapeutics, Waltham, 2TScan Therapeutics, Waltham, MA

    Background/Purpose: Selective modulation of autoimmune responses through antigen-specific therapies represents a promising direction for improving treatment specificity and safety. Genetic associations with HLA class II…
  • Abstract Number: 0948 • ACR Convergence 2025

    Presentation of Apoptotic Cell-Derived Autoantigens in Systemic Autoimmune Disease

    Lance Peterson1, Hannah KL De Cleene2, Cheryl Lichti2, David Bending3 and Kodi Ravichandran2, 1Rheumatology and Immunology, Pediatrics, Washington University School of Medicine, St. Louis, MO, 2Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 3Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, England, United Kingdom

    Background/Purpose: Systemic lupus erythematosus is a chronic, multisystem autoimmune disease characterized by the dysregulated clearance of dying cells, which results in the release of damage-associated…
  • Abstract Number: 0924 • ACR Convergence 2025

    Human Serum Albumin Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Bind Multiple Scavenger Receptors and Alter Cellular Morphology

    Lauren Klingemann1, Michael Duryee1, Nozima Aripova1, Wenxian Zhou2, Hannah Johnson1, Breanna Butler1, Carlos Hunter1, Ted Mikuls1 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Bellevue, NE

    Background/Purpose: Post-translational modifications (PTMs) of self-proteins are implicated in the pathogenesis of rheumatoid arthritis (RA). The PTMs, malondialdehyde-acetaldehyde (MAA), citrulline (CIT), and the co-modification of…
  • Abstract Number: 0923 • ACR Convergence 2025

    Influenza Virus Infection Alters the MHC Class II Self-Immunopeptidome to Present Lupus-Associated Autoantigens

    Julia Rood1, Stephanie Suh Kyung Yoon2, Mary Heard1, Michael Hogan2, Nicola Ternette3, Edward Behrens4 and Laurence Eisenlohr1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Dundee, Dundee, Scotland, United Kingdom, 4CHOP, West Chester, PA

    Background/Purpose: Viral infections and major histocompatibility complex class II (MHC II) are both implicated in the genesis of systemic lupus erythematosus (SLE), but a mechanistic…
  • Abstract Number: 0921 • ACR Convergence 2025

    Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling

    Hannah Johnson1, Wenxian Zhou2, Michael Duryee1, Carlos Hunter1, Geoffrey Thiele1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Bellevue, NE

    Background/Purpose: Citrulline (CIT) and malondialdehyde-acetaldehyde (MAA) co-adduct native proteins in RA tissues to create a dual pro-inflammatory and pro-fibrotic milieu. Our previous work demonstrated that…
  • Abstract Number: 0033 • ACR Convergence 2024

    Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles

    Linda Mathsson-Alm1, Helga Westerlind2, Isabel Gehring3, Monika Hansson2, Nasim Ghasemzadeh1, Jessica Rojas-Restrepo3, Saedis Saevarsdottir4, Joseph Sexton5, Siri Lillegraven6, Espen Haavardsholm6, Merete Hetland7, Hilde Hammer8, Tore K. Kvien9, Bente Glintborg10, Leonid Padyukov2, Johan Askling2 and Caroline Grönwall2, and the Danish Rheumatologic Biobank Study Group (the Biomarker Protocol), Swedish Rheumatology Quality Register Biobank Study Group (SRQb), 1Thermo Fisher Scientific, Uppsala, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Thermo Fisher Scientific, Freiburg, Germany, 4University of Iceland, Reykjavik, Iceland, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Diakonhjemmet Hospital, Oslo, Norway, 7Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, 8Diakonhjemmet Hospital, Oslo, Oslo, Norway, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 10DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark

    Background/Purpose: Carriage of HLA-DRB1 shared epitope (SE) alleles and a history of smoking, have been identified as the most prominent risk factors for development of…
  • Abstract Number: 0039 • ACR Convergence 2024

    Blockade of Soluble and Cell Surface PAD Activity Prevents the Generation of Citrullinated Autoantigens Recognized by RA Patients’ Serum

    Lacie Scaletta1, Teneema Kuriakose1, Sambit Nanda1, Mia Collins2, Erika Darrah3, Iain McInnes4, David Close5 and Gary Sims1, 1Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 3Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 4University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 5Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: Anti-citrullinated protein autoantibodies (ACPA) promote inflammation and joint tissue injury and define a poor prognostic group of patients with rheumatoid arthritis (RA). Citrullinated autoantigens…
  • Abstract Number: 0320 • ACR Convergence 2024

    Comparative Transcriptional Profiling Reveals Shared Pathway Activation Between Human Jo-1+ Anti-Synthetase Syndrome and Murine Histidyl-tRNA Synthetase-Induced Myositis

    Iago Pinal-Fernandez1, Daniel Reay2, Timothy Oriss2, katherine Pak3, Maria Casal-Dominguez4, jose milisenda5, Albert Selva-O’Callaghan6, Werner Stenzel7, Andrew Mammen1 and Dana Ascherman8, 1NIH, Bethesda, MD, 2University of Pittsburgh School of Medicine, Pittsburgh, PA, 3National Institutes of Health, Bethesda, MD, 4NIH, Bathesda, MD, 5Hospital Clinic de Barcelona, Barcelona, Spain, 6Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, 7Charite University, Berlin, Germany, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA

    Background/Purpose: Previous work has shown unique gene expression profiles in muscle tissue corresponding to the anti-synthetase syndrome, with an emphasis on interferon gene signatures (Type…
  • Abstract Number: 0837 • ACR Convergence 2024

    Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome

    Yuanxuan Xia1, Jin Liu1, Alexander Pearlman1, Brian Mog1, Elana Shaw1, Kyle J. Kaeo1, Colin Gliech1, Brock Moritz1, Tolulope Awosika1, Sarah DiNapoli1, Stephanie Glavaris1, Jiaxin Ge1, Tushar Nichakawade1, Nikita Marcou1, Suman Paul1, Drew Pardoll1, Chetan Bettegowda1, Daniel Goldman2, Michelle Petri2, Antony Rosen1, Kenneth W. Kinzler1, Shibin Zhou1, Bert Vogelstein1 and Maximilian F. Konig1, 1The Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Available drugs to treat autoimmune diseases are indiscriminate, suppressing self-reactive and protective immune responses alike. This lack of therapeutic precision results in infection and…
  • Abstract Number: 0892 • ACR Convergence 2024

    Peptides from Candidate Sjögren’s Disease Autoantigens and Salivary Gland Tissue-Enriched Proteins Eluted from Human Salivary Gland HLA-DR

    Tommi C. Taylor1, Sri Ramarathinam2, Shan Zou Chung2, Kirti Pandey2, Ananth Aditya Jupudi1, Bhuwan Khatri3, Sherri Longobardi3, Charmaine Lopez-Davis3, Astrid Rasmussen3, Kiely Grundahl3, Robert Hal Scofield3, Christopher Lessard3, Linda F. Thompson3, Anthony W. Purcell2 and A. Darise Farris3, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Monash University, Clayton, Victoria, Australia, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Sjögren’s Disease (SjD) is characterized by aberrant autoimmune reactions in lacrimal and salivary glands (SG) leading to severe dryness. Evidence for B cell help…
  • Abstract Number: 0923 • ACR Convergence 2024

    Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde Modified Vimentin Induces Post-Translational Protein Modifications and Extracellular Matrix Deposition in Heart Tissues

    Kimberley Sinanan1, Wenxian Zhou2, Michael Duryee1, Nozima Aripova1, Jill Poole1, Carlos Hunter1, Amy Nelson1, Tate Johnson1, Daniel Anderson3, Ted Mikuls1 and Geoffrey Thiele1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Bellevue, NE, 3University of Nebraska Medical Center, Durham, NC

    Background/Purpose: Recent studies have highlighted the importance of malondialdehyde-acetaldehyde (MAA)-modified proteins and resulting immune responses in the pathogenesis of rheumatoid arthritis (RA). MAA adducts have…
  • Abstract Number: 0963 • ACR Convergence 2024

    Stratification According to Autoantibody Status in Systemic Sclerosis Reveals Distinct Molecular Signatures

    Bénédicte ROUVIERE1, Christelle Le dantec2, Eléonore Bettacchioli3, Lorenzo Beretta4, Céline Cao2, Christophe Jamin2, Jacques-Olivier Pers5, Nathan Foulquier2, Martin Kerick6, Javier Martin6, Marta Alarcon-Riquelme7, Claire de Moreuil8, Divi Cornec3 and Sophie Hillion2, and PRECISESADS Clinical Consortium, PRECISESADS Metabolomic Study Group, 1CHRU de Brest, LBAI. UMR 1227, University of Brest, Brest, France, 2LBAI. UMR 1227, University of Brest, Brest, France, 3Service de Rhumatologie, CHU de Brest, Brest, France, 4Scleroderma Unit, Fondazione IRCCS Ca' Granda, University of Milan, Milan, Italy, 5University of Brest, Brest, France, 6Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Spain, Granada, Spain, 7Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 8Service de médecine interne, CHU de Brest, Brest, France

    Background/Purpose: Systemic sclerosis is a heterogeneous disease, complicating its management. Its complexity and the insufficiency of clinical manifestations alone to delineate homogeneous patient groups further…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology